NEONC TECHNOLOGIES HOLDINGS, INC.
NTHI$68M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCALABASAS
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Q4 2026
Market Overview
Stock performance and key metrics
NTHI News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
NEO212 Oral Capsule
Diffuse Astrocytoma, IDH-Mutant
Perillyl alcohol
Glioblastoma Multiforme
NEO100
Residual, Progressive or Recurrent Grade II or III Meningioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NEO212 Oral Capsule | Phase 2 | Diffuse Astrocytoma, IDH-Mutant | - | - |
Perillyl alcohol | Phase 2 | Glioblastoma Multiforme | - | - |
NEO100 | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply